In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 4.14% outpaced the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $708.75 million, indicating a 7.4% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.54 per share and a revenue of $2.84 billion, indicating changes of +14.79% and +12.38%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Medpace is presently being traded at a Forward P/E ratio of 35.35. This denotes a premium relative to the industry average Forward P/E of 17.86.
It's also important to note that MEDP currently trades at a PEG ratio of 2.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.67.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 101, placing it within the top 42% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MEDP in the coming trading sessions, be sure to utilize Zacks.com.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).